{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:39:05Z","timestamp":1761100745916},"reference-count":84,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To optimize treatment outcomes for hematologic malignancies, minimizing the consequences of treatment complications requires as much skill as the choice of the treatment itself. Myelosuppression and immunosuppression are frequent complications and have potentially serious infectious consequences. Invasive fungal infections and infections from respiratory viruses are increasing in frequency and have life-threatening potential. Damage to vital organs, especially the liver, is another important concern. In this chapter, the scope of invasive fungal and respiratory viral infections, recent insights into the pathogenesis of hepatic sinusoidal injury, and recent developments that impact prevention and treatment approaches for these complications are described.<\/jats:p>\n               <jats:p>In Section I, Dr. John Wingard describes the advantages and disadvantages of various treatment options for invasive infections by the two chief fungal pathogens, Candida and Aspergillus. Adjunctive therapies and practical considerations that clinicians should weigh in choosing one or another of the various agents are discussed. The studies that have evaluated antifungal prophylaxis and empirical treatment strategies are reviewed. Finally, new approaches such as combination therapy, new diagnostics, and efforts to bolster host immunity are considered.<\/jats:p>\n               <jats:p>In Section II, Dr. W. Garrett Nichols describes the epidemiology of community-acquired respiratory viruses (CRV) in patients with hematologic malignancies. Risk factors, clinical syndromes, and possible indirect effects of CRV infections are discussed. Treatment and prevention options are reviewed.<\/jats:p>\n               <jats:p>In Section III, Dr. George McDonald describes sinusoidal obstruction syndrome (once known as hepatic veno-occlusive disease). Recent insights into pathogenesis are described. Diagnostic criteria and the advantages and disadvantages of various diagnostic methods are reviewed and prognosis is considered. Prevention and treatment options are discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.372","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"372-389","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Supportive Care"],"prefix":"10.1182","volume":"2004","author":[{"given":"John R.","family":"Wingard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Garrett","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George B.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021215282321600_R1","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004;10 (Suppl 1):11\u201323.","DOI":"10.1111\/j.1470-9465.2004.t01-1-00844.x"},{"key":"2020021215282321600_R2","unstructured":"Anaissie EJ, White M, Ozun O, et al. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial. (Poster Session). In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: ASM Press. 1995: Abstract #330."},{"key":"2020021215282321600_R3","doi-asserted-by":"crossref","unstructured":"Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161\u2013189.","DOI":"10.1086\/380796"},{"key":"2020021215282321600_R4","doi-asserted-by":"crossref","unstructured":"Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections. Bone Marrow Transplant. 2004;34(1):13\u201320.","DOI":"10.1038\/sj.bmt.1704516"},{"key":"2020021215282321600_R5","unstructured":"Marr K, Hachem R, Papanicolaou G, et al. Retrospective study of concomitant use of caspofungin with cyclosporine A in patients treated during marketed use [abstract]. Blood. 2003;102:471a."},{"key":"2020021215282321600_R6","doi-asserted-by":"crossref","unstructured":"Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020\u20132029.","DOI":"10.1056\/NEJMoa021585"},{"key":"2020021215282321600_R7","doi-asserted-by":"crossref","unstructured":"Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48:2021\u20132024.","DOI":"10.1128\/AAC.48.6.2021-2024.2004"},{"key":"2020021215282321600_R8","unstructured":"Walsh TJ, Sable C, DePauw B, et al. A randomized, double-blind, multicenter trial of caspofungin vs liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients [Abstract M1761]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003."},{"key":"2020021215282321600_R9","doi-asserted-by":"crossref","unstructured":"Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359\u2013366.","DOI":"10.1086\/341401"},{"key":"2020021215282321600_R10","doi-asserted-by":"crossref","unstructured":"Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27:1406\u20131412.","DOI":"10.1086\/515033"},{"key":"2020021215282321600_R11","doi-asserted-by":"crossref","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408\u2013415.","DOI":"10.1056\/NEJMoa020191"},{"key":"2020021215282321600_R12","unstructured":"Maertens J, Raad I, Sable CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations or azole. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: ASM Press. Abstract #1103. 2000."},{"key":"2020021215282321600_R13","doi-asserted-by":"crossref","unstructured":"Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221\u20131228.","DOI":"10.1086\/374850"},{"key":"2020021215282321600_R14","doi-asserted-by":"crossref","unstructured":"Aliff TB, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025\u20131032.","DOI":"10.1002\/cncr.11115"},{"key":"2020021215282321600_R15","doi-asserted-by":"crossref","unstructured":"Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292\u2013299.","DOI":"10.1002\/cncr.11479"},{"key":"2020021215282321600_R16","doi-asserted-by":"crossref","unstructured":"Wheat LJ. Combination therapy for aspergillosis: is it needed, and which combination? J Infect Dis. 2003;187:1831\u20131833.","DOI":"10.1086\/375418"},{"key":"2020021215282321600_R17","doi-asserted-by":"crossref","unstructured":"Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693\u2013715.","DOI":"10.1128\/AAC.48.3.693-715.2004"},{"key":"2020021215282321600_R18","unstructured":"Van Burik J-A, Ratanatharathorn V, Lipton J, et al. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). [Abstract M1238]. Washington, DC: American Society for Microbiology, 2002."},{"key":"2020021215282321600_R19","doi-asserted-by":"crossref","unstructured":"Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer. 2000;89:1611\u20131625.","DOI":"10.1002\/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B"},{"key":"2020021215282321600_R20","doi-asserted-by":"crossref","unstructured":"Glasmacher, A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21:4615\u20134626.","DOI":"10.1200\/JCO.2003.04.052"},{"key":"2020021215282321600_R21","doi-asserted-by":"crossref","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705\u2013713.","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"2020021215282321600_R22","doi-asserted-by":"crossref","unstructured":"Marr K, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527\u20131533.","DOI":"10.1182\/blood-2003-08-2644"},{"key":"2020021215282321600_R23","doi-asserted-by":"crossref","unstructured":"Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant. 2004;10(7): 494\u2013503.","DOI":"10.1016\/j.bbmt.2004.02.006"},{"key":"2020021215282321600_R24","doi-asserted-by":"crossref","unstructured":"Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39(1):S38\u2013S43.","DOI":"10.1086\/383052"},{"key":"2020021215282321600_R25","doi-asserted-by":"crossref","unstructured":"Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604\u20131610.","DOI":"10.1182\/blood.V97.6.1604"},{"key":"2020021215282321600_R26","doi-asserted-by":"crossref","unstructured":"Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002;20:1898\u20131906.","DOI":"10.1200\/JCO.2002.07.004"},{"key":"2020021215282321600_R27","doi-asserted-by":"crossref","unstructured":"Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med. 2003;349:2366\u20132367.","DOI":"10.1056\/NEJM200312113492424"},{"key":"2020021215282321600_R28","doi-asserted-by":"crossref","unstructured":"Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199\u2013205.","DOI":"10.1086\/421944"},{"key":"2020021215282321600_R29","doi-asserted-by":"crossref","unstructured":"Lin MT, Lu HC, Chen WL, et al. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis. 2001;33:1621\u20131627.","DOI":"10.1086\/322631"},{"key":"2020021215282321600_R30","doi-asserted-by":"crossref","unstructured":"Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:1\u201323.","DOI":"10.1038\/nri1255"},{"key":"2020021215282321600_R31","doi-asserted-by":"crossref","unstructured":"BitMansour A, Burns SM, Traver D, et al. Myeloid progenitors protect against invasive aspergillosis and Pseudomonas aeruginosa infection following hematopoietic stem cell transplantation. Blood. 2002;100:4660\u20134667.","DOI":"10.1182\/blood-2002-05-1552"},{"key":"2020021215282321600_R32","doi-asserted-by":"crossref","unstructured":"Bozza S, Perruccio K, Montagnoli, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood. 2003;102(10):3807\u20133814.","DOI":"10.1182\/blood-2003-03-0748"},{"key":"2020021215282321600_R33","doi-asserted-by":"crossref","unstructured":"Ramadan G, Konings S, Kurup VP, Keever-Taylor CA. Generation of aspergillus- and CMV-specific T-cell responses using autologous fast DC. Cytotherapy. 2004; 6: 223\u2013234.","DOI":"10.1080\/14653240410006040"},{"key":"2020021215282321600_R34","doi-asserted-by":"crossref","unstructured":"Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 Suppl:11S\u201315S.","DOI":"10.1053\/bbmt.2001.v7.pm11777098"},{"key":"2020021215282321600_R35","doi-asserted-by":"crossref","unstructured":"Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med.1997;102:27\u201330; discussion 42-23.","DOI":"10.1016\/S0002-9343(97)00007-7"},{"key":"2020021215282321600_R36","unstructured":"Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994;13:437\u2013440."},{"key":"2020021215282321600_R37","doi-asserted-by":"crossref","unstructured":"Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778\u2013782.","DOI":"10.1093\/clinids\/22.5.778"},{"key":"2020021215282321600_R38","doi-asserted-by":"crossref","unstructured":"Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479\u2013484.","DOI":"10.1038\/sj.bmt.1703139"},{"key":"2020021215282321600_R39","doi-asserted-by":"crossref","unstructured":"Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98:573\u2013578.","DOI":"10.1182\/blood.V98.3.573"},{"key":"2020021215282321600_R40","doi-asserted-by":"crossref","unstructured":"Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after stem cell transplantation: risk factors, mortality and the effect of antiviral therapy. Biol Blood Marrow Transplant. 2003;9:73\u201374.","DOI":"10.1016\/S1083-8791(03)80035-6"},{"key":"2020021215282321600_R41","doi-asserted-by":"crossref","unstructured":"van Elden LJ, van Kraaij MG, Nijhuis M, et al. Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Clin Infect Dis. 2002;34:177\u2013183.","DOI":"10.1086\/338238"},{"key":"2020021215282321600_R42","doi-asserted-by":"crossref","unstructured":"van Elden LJ, van Loon AM, van der Beek A, et al. Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J Clin Microbiol. 2003;41:4378\u20134381.","DOI":"10.1128\/JCM.41.9.4378-4381.2003"},{"key":"2020021215282321600_R43","unstructured":"Englund JA, Whimbey EE. Community-acquired respiratory viruses after hemopoietic stem cell or solid organ transplantation. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. Philadelphia: Lippincott, Williams & Wilkins; 2003:375\u2013398."},{"key":"2020021215282321600_R44","doi-asserted-by":"crossref","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358\u20134366.","DOI":"10.1182\/blood-2002-05-1496"},{"key":"2020021215282321600_R45","doi-asserted-by":"crossref","unstructured":"Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol. 2002;119:1125\u20131132.","DOI":"10.1046\/j.1365-2141.2002.03992.x"},{"key":"2020021215282321600_R46","doi-asserted-by":"crossref","unstructured":"Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31:695\u2013700.","DOI":"10.1038\/sj.bmt.1703900"},{"key":"2020021215282321600_R47","doi-asserted-by":"crossref","unstructured":"Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32:1085\u20131088.","DOI":"10.1038\/sj.bmt.1704257"},{"key":"2020021215282321600_R48","doi-asserted-by":"crossref","unstructured":"Anaissie EJ, Mahfouz TH, Aslan T, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood. 2004;103:1611\u20131617.","DOI":"10.1182\/blood-2003-05-1425"},{"key":"2020021215282321600_R49","doi-asserted-by":"crossref","unstructured":"Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992;165:987\u2013993.","DOI":"10.1093\/infdis\/165.6.987"},{"key":"2020021215282321600_R50","doi-asserted-by":"crossref","unstructured":"Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350\u2013354.","DOI":"10.1086\/322043"},{"key":"2020021215282321600_R51","unstructured":"Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis. 1984;129:641\u2013644."},{"key":"2020021215282321600_R52","doi-asserted-by":"crossref","unstructured":"Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;33:759\u2013764.","DOI":"10.1038\/sj.bmt.1704422"},{"key":"2020021215282321600_R53","doi-asserted-by":"crossref","unstructured":"Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208\u2013214.","DOI":"10.1164\/rccm.200212-1468OC"},{"key":"2020021215282321600_R54","doi-asserted-by":"crossref","unstructured":"Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med. 1989;111:368\u2013376.","DOI":"10.7326\/0003-4819-111-5-368"},{"key":"2020021215282321600_R55","doi-asserted-by":"crossref","unstructured":"Pelletier G, Dery P, Abed Y, Boivin G. Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. Emerg Infect Dis. 2002;8:976\u2013978.","DOI":"10.3201\/eid0809.020238"},{"key":"2020021215282321600_R56","doi-asserted-by":"crossref","unstructured":"Cane PA, Van Den Hoogen BG, Chakrabarti S, Fegan CD, Osterhaus AD. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. 2003;31:309\u2013310.","DOI":"10.1038\/sj.bmt.1703849"},{"key":"2020021215282321600_R57","doi-asserted-by":"crossref","unstructured":"Ghosh S, Champlin R, Couch R, et al. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis. 1999;29:528\u2013532.","DOI":"10.1086\/598627"},{"key":"2020021215282321600_R58","doi-asserted-by":"crossref","unstructured":"Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis. 2003;36:1139\u20131143.","DOI":"10.1086\/374340"},{"key":"2020021215282321600_R59","doi-asserted-by":"crossref","unstructured":"Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:321\u2013327.","DOI":"10.1038\/sj.bmt.1703365"},{"key":"2020021215282321600_R60","doi-asserted-by":"crossref","unstructured":"DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH, Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant. 2000;25:161\u2013165.","DOI":"10.1038\/sj.bmt.1702118"},{"key":"2020021215282321600_R61","doi-asserted-by":"crossref","unstructured":"Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998;26:1418\u20131424.","DOI":"10.1086\/516358"},{"key":"2020021215282321600_R62","doi-asserted-by":"crossref","unstructured":"Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:113\u2013115.","DOI":"10.1038\/sj.bmt.1703343"},{"key":"2020021215282321600_R63","unstructured":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2000;6:659\u2013713;715;717\u2013627."},{"key":"2020021215282321600_R64","doi-asserted-by":"crossref","unstructured":"DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29:1779\u20131791.","DOI":"10.1002\/hep.510290615"},{"key":"2020021215282321600_R65","doi-asserted-by":"crossref","unstructured":"Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venocclusive disease of the liver after marrow transplantation: histologic correlates of clinical signs and symptoms. Hepatology. 1994;19:1171\u20131180.","DOI":"10.1002\/hep.1840190515"},{"key":"2020021215282321600_R66","doi-asserted-by":"crossref","unstructured":"Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis. 2002;22:27\u201341.","DOI":"10.1055\/s-2002-23204"},{"key":"2020021215282321600_R67","doi-asserted-by":"crossref","unstructured":"Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406\u2013413.","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U"},{"key":"2020021215282321600_R68","doi-asserted-by":"crossref","unstructured":"Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction following gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:4245\u20134246.","DOI":"10.1182\/blood.V99.7.2310"},{"key":"2020021215282321600_R69","doi-asserted-by":"crossref","unstructured":"McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043\u20132048.","DOI":"10.1182\/blood-2002-06-1860"},{"key":"2020021215282321600_R70","doi-asserted-by":"crossref","unstructured":"DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60:143\u2013154.","DOI":"10.1159\/000028359"},{"key":"2020021215282321600_R71","unstructured":"Meresse V, Hartmann O, Vassal G, et al. Risk factors of hepatic venocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10:135\u2013141."},{"key":"2020021215282321600_R72","doi-asserted-by":"crossref","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578\u20131582.","DOI":"10.1182\/blood-2003-01-0255"},{"key":"2020021215282321600_R73","doi-asserted-by":"crossref","unstructured":"Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology. 2000;31:428\u2013434.","DOI":"10.1002\/hep.510310224"},{"key":"2020021215282321600_R74","doi-asserted-by":"crossref","unstructured":"Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology. 2003;125:882\u2013890.","DOI":"10.1016\/S0016-5085(03)01056-4"},{"key":"2020021215282321600_R75","doi-asserted-by":"crossref","unstructured":"DeLeve LD, Wang X, Kanel GC, et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology. 2003;38:900\u2013908.","DOI":"10.1002\/hep.1840380416"},{"key":"2020021215282321600_R76","doi-asserted-by":"crossref","unstructured":"McCarville MB, Hoffer FA, Howard SC, Goloubeva O, Kauffman WM. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: usefulness of sonographic findings. Pediatr Radiol. 2001;31:102\u2013105.","DOI":"10.1007\/s002470000373"},{"key":"2020021215282321600_R77","doi-asserted-by":"crossref","unstructured":"Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280\u2013282.","DOI":"10.1002\/hep.20062"},{"key":"2020021215282321600_R78","doi-asserted-by":"crossref","unstructured":"Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplant with severe veno-occlusive disease and multi-system organ failure: response without significant toxicity in a high risk population and factors predictive of outcome. Blood. 2002;100:4337\u20134343.","DOI":"10.1182\/blood-2002-04-1216"},{"key":"2020021215282321600_R79","doi-asserted-by":"crossref","unstructured":"Ringden O, Remberger M, Lehmann S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;25:993\u2013996.","DOI":"10.1038\/sj.bmt.1702387"},{"key":"2020021215282321600_R80","doi-asserted-by":"crossref","unstructured":"Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25:915\u2013924.","DOI":"10.1038\/sj.bmt.1702377"},{"key":"2020021215282321600_R81","doi-asserted-by":"crossref","unstructured":"Slattery JT. Re: intravenous versus oral busulfan\u2014perhaps not as different as suggested. Biol Blood Marrow Transplant. 2003;9:282\u2013284.","DOI":"10.1053\/bbmt.2003.50029"},{"key":"2020021215282321600_R82","doi-asserted-by":"crossref","unstructured":"Bornhauser M, Storer B, Slattery J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820\u2013826.","DOI":"10.1182\/blood-2002-11-3567"},{"key":"2020021215282321600_R83","doi-asserted-by":"crossref","unstructured":"Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood. 2004;103:1968.","DOI":"10.1182\/blood-2003-10-3612"},{"key":"2020021215282321600_R84","doi-asserted-by":"crossref","unstructured":"Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977\u20131983.","DOI":"10.1182\/blood-2001-12-0159"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/372\/1634514\/372_389ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/372\/1634514\/372_389ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:29:39Z","timestamp":1581539379000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/372\/18691\/Supportive-Care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.372","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}